Spinosyn Formulation for Equine Bot Larvae Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for equine bot infestations, such as those caused by Gasterophilus species, face limitations including toxicity, safety concerns, efficacy, resistance issues, and administration challenges, with existing internal therapies requiring frequent dosing and having variable effectiveness.
Innovation Solution
The use of spinosyns, naturally derived fermentation products like spinosyn A and spinosyn D, administered orally in formulations with physiologically acceptable carriers, provides an alternative therapy for controlling or treating bot larvae in the gastrointestinal tract of equine animals, offering improved safety and prolonged efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad spectrum products containing avermectin are used to treat bots, then boticidal activity is achieved, but nematode resistance develops and additional agents are required
Solution Approach 1:
The patent changes the chemical parameter of the treatment agent from avermectin to spinosyn, a different class of compound with distinct mode of action. This parameter change achieves boticidal activity while avoiding cross-resistance with nematodes, as spinosyns have different target sites and mechanisms compared to avermectins and benzimidazoles.
2Reliability
If current internal therapies are administered frequently to maintain efficacy, then bot control is improved, but administration difficulty and inconvenience increase
Solution Approach 1:
The patent uses spinosyn at doses that provide excessive or super-therapeutic levels of boticidal activity, achieving near-complete elimination of bots (90-100% reduction). This excessive action allows for extended treatment intervals because the compound maintains effective concentrations longer and achieves more complete parasite clearance, reducing the frequency of re-dosing needed.
3Object-affected harmful factors
If spinosyn is administered orally at low doses, then safety profile is improved, but boticidal efficacy may be reduced
Solution Approach 1:
The patent employs dynamic dosing strategies where spinosyn is administered at optimized doses that balance safety and efficacy. The dosing regimen is adjusted based on the bot infestation level, horse weight, and treatment response, allowing low doses for maintenance or light infestations while permitting higher doses when needed for severe cases, thus dynamically optimizing the safety-efficacy balance.
Data Source
AI summary
Provided are novel methods and formulations for orally controlling bot larvae in the gastrointestinal tract of equine animal using a spinosyn.